Benjamin Besse

Research interests

Publications

• Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00518-6

• Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

  Nature Cancer · 2021 · https://doi.org/10.1038/s43018-021-00232-6

• Sotorasib for Lung Cancers with KRAS p.G12C Mutation

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2103695

• Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00247-3

• Caring for patients with cancer in the COVID-19 era

  Nature Medicine · 2020 · https://doi.org/10.1038/s41591-020-0874-8

• Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30068-1

• Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2005653

• Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(19)30691-6

• Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz167

• Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

  Journal of Thoracic Oncology · 2019 · https://doi.org/10.1016/j.jtho.2019.07.025

• Hyperprogressive disease: recognizing a novel pattern to improve patient management

  Nature Reviews Clinical Oncology · 2018 · https://doi.org/10.1038/s41571-018-0111-2

• Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

  JAMA Oncology · 2018 · 10.1001/jamaoncol.2017.4771

• Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease

  European Journal of Cancer · 2018 · https://doi.org/10.1016/j.ejca.2017.12.008

• Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study

  The Lancet Haematology · 2018 · https://doi.org/10.1016/s2352-3026(18)30175-3

• Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30649-1

• Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30679-4

• Targeting RET in Patients With RET -Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2016.70.9352

• Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

  The Lancet · 2016 · https://doi.org/10.1016/s0140-6736(16)00004-0

• Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30146-2

• SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas

  Nature Genetics · 2015 · https://doi.org/10.1038/ng.3399

• Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study

  Clinical Cancer Research · 2015 · https://doi.org/10.1158/1078-0432.ccr-14-2082

• 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

  Annals of Oncology · 2014 · https://doi.org/10.1093/annonc/mdu123

• Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

  Annals of Oncology · 2014 · https://doi.org/10.1093/annonc/mdu145

• 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

  Annals of Oncology · 2014 · https://doi.org/10.1093/annonc/mdu123

• 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

  Annals of Oncology · 2014 · https://doi.org/10.1093/annonc/mdu089

• Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1214886

• Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.45.6095

• Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

  Nature Genetics · 2012 · https://doi.org/10.1038/ng.2396

Current projects

No projects listed.